#5e2d92_SMALL_Nov-Dec 2024 DRA Journal Cover

From myth-busting photobiomodulation therapy to showcasing advanced aesthetic cases, this issue delivers practical insights for modern dental practice. Explore evidence-based techniques in implant and veneer rehabilitation, essential guidance on monkeypox protocols, and strategies for enhanced patient communication.

>> FlipBook Version (Available in English)

>> Mobile-Friendly Version (Available in Multiple Languages)

Click here to access Asia's first Open-Access, Multi-Language Dental Publication

Balanced Pharma Receives Patent for Acid-Free Dental Anesthetic Cartridge

US: Balanced Pharma, a pharmaceutical company headquartered near Charlotte, North Carolina, has been granted a second patent by the United States Patent & Trademark Office for its innovative cartridge technology. 

Their patented technology allows for the delivery of acid-free local anesthetics in a standard dental cartridge. By eliminating the presence of acid in anesthetics, Balanced Pharma’s new cartridge aims to enhance patient comfort, provide faster-acting numbing injections, and ensure greater reliability.

Balanced Pharma’s flagship drug candidate, BPI-001, is specifically designed as a local anesthetic for the dental market. It will be supplied in a standard dental cartridge. The buffered lidocaine/epinephrine formulation of BPI-001 is notable for its absence of acid, which is typically found in conventional local anesthetics.

Benefits of Acid-Free Local Anesthetics

Multiple studies have demonstrated the advantages of removing acid from local anesthetics, including faster onset, reduced injection pain, and improved reliability. Particularly noteworthy is an April 2023 study published in the British Journal of Oral and Maxillofacial Surgery, which involved a significant number of patients and yielded statistically significant results. The findings further support the potential impact of Balanced Pharma’s new cartridge technology.

According to Balanced Pharma, market research indicates that more than half of surveyed patients consider the injection process to be the most unpleasant aspect of their dental experience. Recognizing this need, Balanced Pharma commissioned a comprehensive survey conducted by the Olson Research Group, which involved 181 dentists and 140 dental patients across the United States.

“It was hard to tell who is more excited about this product—patients or dentists,” said Dr Scott Keadle, CEO of Balanced Pharma. 

“We’re proud to be a company founded by practicing clinicians, working to deliver a product to provide patients more comfort. We knew if we could provide acid-free anesthetic in a standard cartridge, that would be a huge win for providers and patients, and we’re well-poised to deliver on that promise.”

Click here for more information on BPI-001 by Balanced Pharma.

The information and viewpoints presented in the above news piece or article do not necessarily reflect the official stance or policy of Dental Resource Asia or the DRA Journal. While we strive to ensure the accuracy of our content, Dental Resource Asia (DRA) or DRA Journal cannot guarantee the constant correctness, comprehensiveness, or timeliness of all the information contained within this website or journal.

Please be aware that all product details, product specifications, and data on this website or journal may be modified without prior notice in order to enhance reliability, functionality, design, or for other reasons.

The content contributed by our bloggers or authors represents their personal opinions and is not intended to defame or discredit any religion, ethnic group, club, organisation, company, individual, or any entity or individual.

Leave a Reply

Your email address will not be published. Required fields are marked *